Publications

5808 Results

Fulvestrant alone versus fulvestrant and everolimus versus fulvestrant, everolimus and anastrozole: A Phase III randomized, placebo-controlled trial in postmenopausal patients with hormone-receptor-positive stage IV breast cancer: SWOG-Clinical Trials Initiative (CTI)* S1222

Authors
G Somlo;W Barlow;HCF Moore;J Gralow;A Schott;DF Hayes;P Kuhn;JB Hicks;DL Lew;D Tripathy;G Hortobagyi
Journal / Conference
San Antonio Breast Cancer Symposium Annual Meeting (December 9-13, 2014, San Antonio, TX), abstr. [OT2-1-01], poster;
Year
2014
Research Committee(s)
Breast
Study Number(s)
S1222

Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single arm phase II trials

Authors
PA Philip;K Chansky;L Rubenstein;M Leblanc;L Seymour;SP Ivy;SR Alberts;PJ Catalano;J Crowley
Journal / Conference
Clinical Cancer Research 20(16):4176-4185;
Year
2014
Research Committee(s)
Gastrointestinal
PMID
PMID24914040
PMC
PMC4296727
Study Number(s)
S0107, S0205, SWOG-8916, SWOG-8933, SWOG-9100, SWOG-9135, SWOG-9413, S9629, S9924

Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity

Authors
JA Sparano;RJ Gray;TJ Whelan;K Albain;D Hayes;C Geyer;EC Dees;EA Perez;JA Olson;MM Keane;C Sologuren;R Reddi;TF Goggins;IA Mayer;AM Brufsky;DL Toppmeyer;V Kaklamani;JN Atkins;J Berenberg;GW Sledge
Journal / Conference
Journal of Clinical Oncology Vol 32, No 26_suppl, 2014: 36; ASCO Breast Cancer Symposium (September 4-6, 2014, San Francisco, CA);
Year
2014
Research Committee(s)
Breast

Capecitabine and oxaliplatin in the preoperative multi-modality treatment of rectal cancer: surgical end points from national surgical adjuvant breast and bowel project trial R-04

Authors
MJ O'Connell;LH Colangelo;RW Beart;NJ Petrilli;CJ Allegra;S Sharif;HC Pitot;AF Shields;JC Landry;DP Ryan;DS Parda;M Mohiuddin;A Arora;L Evans;N Bahary;G Soori;J Eakle;JM Robertson;DF Moore;M Mullane;BT Marchello;PJ Ward;TF Wozniak;MS Roh;G Yothers;N Wolmark
Journal / Conference
Journal of Clinical Oncology 32(18):1927-1934
Year
2014
Research Committee(s)
Gastrointestinal
PMID
PMID24799484
PMC
PMC4050205

Retention of black and white participants in the Selenium and Vitamin E Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S0000)

Authors
KB Arnold;J Hermos;K Anderson;L Minasian;CM Tangen;J Probstfield;E Cook
Journal / Conference
Cancer Epidemiology, Biomarkers and Prevention 23(12):2895-2905;
Year
2014
Research Committee(s)
Prevention, Screening, and and Surveillance
PMID
PMID25242051
PMC
PMC4257858
Study Number(s)
S0000

Lymphadenectomy at the time of surgery for high risk localized RCC: results from the ASSURE adjuvant trial (ECOG 2805)

Authors
R Uzzo;J Manola;N Haas;C Kane;C Wood;M Jewett;R DiPaola
Journal / Conference
Journal of Urology Vol. 191, No. 4S, Suppl., p. e283 (PD10-04); poster; American Urological Assn Annual Meeting (May 16 -21, 2014, Orlando, FL);
Year
2014
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/E2805

The initial report of RTOG 0524: Phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer

Authors
MD Michaelson;C Hu;HT Pham;MD Dahl;CL Wu;RM Whittington;G Swanson;J Vuky;RJ Lee;L Souhami;BK Chang;A George;HM Sandler;WU Shipley
Journal / Conference
Journal of Clinical Oncology 32(suppl 4; abstr LBA287), oral; ASCO GU Cancers Symposium
Year
2014
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/R0524

Consequences of anorectal cancer atlas implementation in the cooperative group setting: radiobiologic analysis of a prospective randomized in silico target delineation study

Authors
P Mavroidis;D Giantsoudis;M Awan;CRN Rasch;JC Duppen;CR Thomas;P Okunieff;WE Jones;L Kachnic;N Papanikolaou;CD Fuller
Journal / Conference
Radiotherapy and Oncology 112(3):418-424;
Year
2014
Research Committee(s)
Gastrointestinal
PMID
PMID24996454
PMC
PMC4258107
Study Number(s)
S0713

CALGB/SWOG C80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (MCRC)

Authors
H Lenz;D Niedzwiecki;F Innocenti;C Blanke;MR Mahoney;BH O'Neil;JE Shaw;B Polite;H Hochster;J Atkins;RM Goldberg;RJ Mayer;RL Schilsky;M Bertagnolli;A Venook
Journal / Conference
Annals of Oncology 25 (Suppl 4): iv1 - mdu438.66; ESMO 2014 Congress (Sept 26-30, 2014, Madrid, Spain), oral presentation;
Year
2014
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: a prospective pooled analysis of > 11,500 patients from 6 Phase III trials of adjuvant therapy duration with FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) for stage III colon cancer

Authors
D Sargent;J Paul;A Sobrero;T Andre;A Shields;T Yoshino;I Souglakos;T Iveson;R Labianca;J Taieb;JA Meyerhardt;A Ohtsu;A Grothey
Journal / Conference
Annals of Oncology 25 (Suppl 4): iv1 - mdu438.66; ESMO 2014 Congress (September 26-30, 2014, Madrid, Spain), poster presentation;
Year
2014
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702